Recombinant factor VIIa in massive haemoptysis associated with chronic necrotising aspergillosis.
The successful use of recombinant activated factor VII (rFVIIa), in treating massive, life-threatening haemoptysis in a 55-year-old male patient with chronic necrotising aspergillosis, is reported. Patient diagnosed with chronic necrotising aspergillosis three months ago was admitted to our department with massive haemoptysis. Patient was treated as outpatient with itraconazole. One day post-admission, two doses of rFVIIa (30 microg x kg(-1)) were administered and the haemoptysis was successfully resolved. Two further doses of rFVIIa (30 microg x kg(-1) were given the following day, and after that there were no more recurrences of pulmonary haemorrhage. No thromboembolic or other adverse events were observed following rFVIIa therapy. Our findings suggest that use of rFVIIa may represent a safe and effective treatment choice for patients with haemoptysis due to aspergillosis.
Samarzija
Miroslav
M
Department of Post-intensive Care Unit, University Hospital for Lung Diseases "Jordanovac", Zagreb, Croatia.
Srdić
Drazena
D
Redzepi
Gzim
G
Plestina
Sanja
S
Mazuranić
Ivica
I
Jakopović
Marko
M
Miculinić
Neven
N
D000935:Antifungal Agents / Q000627:therapeutic use; D002908:Chronic Disease; D015942:Factor VIIa / Q000008:administration & dosage*; D006469:Hemoptysis / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D055732:Pulmonary Aspergillosis / Q000150:complications*; D011994:Recombinant Proteins / Q000008:administration & dosage; D016896:Treatment Outcome
D000935:Antifungal Agents; D011994:Recombinant Proteins; D017964:Itraconazole; D015942:Factor VIIa